Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 19;3:1. doi: 10.1186/s40959-017-0020-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Crizotinib inhibits HCN4 channel activity. a Protein lysates from non-transfected control HEK-293 cells (CTL) and HEK-293 cells with stable expression of human HCN4 (HCN4) were subjected to sequential immunoblotting (IB) for HCN4 and then tubulin, as indicated. The whole cell patch-clamp technique was then used to assess HCN4 channel activity in HEK-293 cells with stable expression of human HCN4. b Representative traces of I_HCN4 recorded in HCN4-expressing HEK-293 cells before (CTL) and during perfusion with crizotinib (crizo,1 μmol/L). I_HCN4 was elicited by 15 s test pulses from a holding potential of -10 mV to test potentials ranging from −65 to -135 mV (in 10 mV increments) and then back to +20 mV for 2 s to test tail current, followed by return to holding potential (inset). c, Current–voltage (I-V) relationship for I_HCN4 with crizotinib perfusion (crizo, filled circles) and after washout (open circles) (n = 9 per group). Current shown was normalized to membrane capacitance (pA/pF). A significant reduction in HCN4 current density was noted with crizotinib exposure at test potentials from −65 mv to −135 mV (p < 0.05, washout vs. crizotinib treated I-V curves by two-way ANOVA). d Effect of crizotinib on the voltage dependence of HCN4 activation. Activation curves were generated for I_HCN4 with crizotinib perfusion (crizo, filled circles) and after washout (open circles). Crizotinib shifted the activation curve to the left towards more hyperpolarized potentials and shifted the average activation midpoint (V_0.5) (V_0.5 = −84 ± 2 vs. -102 ± 2 mV, washout vs. crizo, p < 0.05). e Average time constants (Tau) of HCN4 channel activation are plotted against test potentials with crizotinib perfusion (filled bars) and after washout (open bars) (n = 11 for each group). Crizotinib resulted in slower HCN4 channel activation at test potentials ≥ −115 mV (*, washout vs. crizo, p < 0.05). f I_HCN4 (normalized to untreated controls) was measured at increasing crizotinib concentrations (0–10 μmol/L) in HCN4-expressing HEK-293 cells. A smooth curve was obtained by fitting the data with the Hill equation. Half-maximal inhibition concentration (IC50) was 1.4 ± 0.3 μmol/L (n = 4–18 at each concentration)